Show simple item record

dc.contributor.authorBurisch, Johan
dc.contributor.authorZhao, Mirabella
dc.contributor.authorOdes, Selwyn
dc.contributor.authorDe Cruz, Peter
dc.contributor.authorVermeire, Severine
dc.contributor.authorBernstein, Charles N
dc.contributor.authorKaplan, Gilaad G
dc.contributor.authorDuricova, Dana
dc.contributor.authorGreenberg, Dan
dc.contributor.authorMelberg, Hans Olav
dc.contributor.authorWatanabe, Mamoru
dc.contributor.authorAhn, Hyeong Sik
dc.contributor.authorTargownik, Laura
dc.contributor.authorPittet, Valérie E H
dc.contributor.authorAnnese, Vito
dc.contributor.authorPark, K.T.
dc.contributor.authorKatsanos, Konstantinos H
dc.contributor.authorHøivik, Marte Lie
dc.contributor.authorKrznaric, Zeljko
dc.contributor.authorChaparro, María
dc.contributor.authorLoftus, Edward V
dc.contributor.authorLakatos, Peter L
dc.contributor.authorGisbert, Javier P
dc.contributor.authorBemelman, Willem
dc.contributor.authorMoum, Bjørn Allan
dc.contributor.authorGearry, Richard B
dc.contributor.authorKappelman, Michael D
dc.contributor.authorHart, Ailsa
dc.contributor.authorPierik, Marieke J
dc.contributor.authorAndrews, Jane M
dc.contributor.authorNg, Siew C
dc.contributor.authorD'Inca, Renata
dc.contributor.authorMunkholm, Pia
dc.date.accessioned2024-02-28T11:57:02Z
dc.date.available2024-02-28T11:57:02Z
dc.date.issued2023-03-02
dc.description.abstractThe cost of caring for patients with inflammatory bowel disease (IBD) continues to increase worldwide. The cause is not only a steady increase in the prevalence of Crohn's disease and ulcerative colitis in both developed and newly industrialised countries, but also the chronic nature of the diseases, the need for long-term, often expensive treatments, the use of more intensive disease monitoring strategies, and the effect of the diseases on economic productivity. This Commission draws together a wide range of expertise to discuss the current costs of IBD care, the drivers of increasing costs, and how to deliver affordable care for IBD in the future. The key conclusions are that (1) increases in health-care costs must be evaluated against improved disease management and reductions in indirect costs, and (2) that overarching systems for data interoperability, registries, and big data approaches must be established for continuous assessment of effectiveness, costs, and the cost-effectiveness of care. International collaborations should be sought out to evaluate novel models of care (eg, value-based health care, including integrated health care, and participatory health-care models), as well as to improve the education and training of clinicians, patients, and policy makers.en_US
dc.identifier.citationBurisch, Zhao, Odes, De Cruz, Vermeire, Bernstein, Kaplan, Duricova, Greenberg, Melberg, Watanabe, Ahn, Targownik, Pittet, Annese, Park, Katsanos, Høivik, Krznaric, Chaparro, Loftus, Lakatos, Gisbert, Bemelman, Moum, Gearry, Kappelman, Hart, Pierik, Andrews, Ng, D'Inca, Munkholm. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology and Hepatology. 2023;8(5):458-492en_US
dc.identifier.cristinIDFRIDAID 2157800
dc.identifier.doi10.1016/S2468-1253(23)00003-1
dc.identifier.issn2468-1253
dc.identifier.issn2468-1156
dc.identifier.urihttps://hdl.handle.net/10037/33075
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.journalThe Lancet Gastroenterology and Hepatology
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
dc.titleThe cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commissionen_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record